4.69
-3.50%
Close of 9 Nov 2026, in USD
Search any instrument
Reference data, closing prices and charts across 45,000 companies, plus crypto, commodities and currencies.
About Alvotech
Its shares trade under the ticker ALVO. It has been listed since 9 November 2020. In the fiscal year to 31 December 2025, it reported revenue of $586.3m and net income of $27.9m. At that date it held total assets of $1.49bn and shareholders' equity of −$284.5m.
Alvotech operates as a global biopharmaceutical company, which engages in developing and manufacturing biosimilar medicines. The firm is focused on the development and manufacture of biosimilar medicines for patients globally. The company is engaged in developing a pipeline of monoclonal antibodies that target a variety of therapeutic areas including inflammatory diseases, oncology, and ophthalmology. The Company’s pipeline contains eight biosimilar candidates aimed at treating autoimmune disorders, eye disorders, osteoporosis, respiratory disease, and cancer. Its products pipeline includes AVT02, AVT04, AVT23, AVT03, AVT05, AVT06, AVT16, and AVT33. Its AVT02 is a monoclonal antibody and a biosimilar to Humira (adalimumab). AVT04 is a monoclonal antibody and a biosimilar candidate to Stelara (ustekinumab). The company has formed a network of strategic commercial partnerships to provide global reach and leverage expertise in markets that include the United States (U.S.), Europe, Japan, China, and other Asian countries and large parts of South America, Africa, and the Middle East.
Figures and description from our data supplier, not checked against the company's own report.
Company facts
- Sector
- Health Care
- Industry
- Biotechnology
- Listed since
- 9 Nov 2020
- Employees
- 1,500
- Head office
- 9, RUE DE BITBOURG, LUXEMBOURG, N4, L-1273
- Incorporated in
- N4
- Classification
- Biological Products, (No Diagnostic Substances)
- Filer status
- Large accelerated filer
Leadership
Pay as last reported
- Mr. Robert WessmanExecutive Chairman of the Board, Chief Executive Officer, Founder, since 2019$2.3m
- Mr. Richard DaviesNon-Executive Independent Deputy Chairman of the Board$339,000
- Ms. Linda JonsdottirChief Financial Officer
- Mr. Joseph McclellanChief Operating Officer
- Ms. Tanya ZharovGeneral Counsel
- Mr. Uri HillelChief Quality Officer
- Mr. Tomas EkmanNon-Executive Independent Director
- Ms. Lisa GraverNon-Executive Independent Director$251,000
- Mr. Arni HardarsonNon-Executive Independent Director
- Dr. Linda McgoldrickNon-Executive Independent Director$275,000
- Ms. Ann MerchantNon-Executive Independent Director$295,000
- Mr. Hjoerleifur PalssonNon-Executive Independent Director$41,000
Environmental, social and governance
Scores out of 100, from our data supplier
- Overall
- 69
- Environment
- 79
- Social
- 89
- Governance
- 40
- Direct emissions (scope 1)
- 20 t
- Energy emissions (scope 2)
- 209 t
- Value chain emissions (scope 3)
- 555 t
- Carbon reduction policy
- No
- Human rights policy
- Yes
SWOT analysis
AI-generated by our data supplier. Not written or checked by our editors.
Strengths
- Alvotech SA has a strong pipeline of eight biosimilar candidates targeting multiple therapeutic areas including inflammatory diseases, oncology, and ophthalmology.
- The company has formed strategic commercial partnerships for global reach across key markets such as the United States, Europe, Japan, China, and parts of South America, Africa, and the Middle East.
- Alvotech SA employs 1500 employees, indicating a substantial workforce for its biopharmaceutical operations.
Weaknesses
- Alvotech SA's IPO occurred in 2020, which may indicate a relatively recent market entry with limited historical financial performance data.
- The company's product pipeline includes specific biosimilar candidates like AVT02 and AVT04, which may face regulatory and market competition challenges.
- Alvotech SA operates in the highly competitive biotechnology sector, which requires significant ongoing investment.
Opportunities
- The global demand for biosimilar medicines continues to grow, offering potential market expansion for Alvotech SA's pipeline products.
- Strategic partnerships with commercial entities could lead to increased market penetration in emerging regions such as Africa and South America.
- The development of monoclonal antibodies for various therapeutic areas presents opportunities for addressing unmet medical needs.
Threats
- The biotechnology sector faces intense competition from established pharmaceutical companies and other biosimilar developers.
- Regulatory hurdles and approval processes for biosimilar medicines can delay market entry and increase development costs.
- Economic downturns or changes in healthcare policies could impact the adoption and reimbursement of biosimilar medicines.
Sources and methodology
- Data on this tab
- Our data supplier
- Chart on the Overview
- TradingView
Nothing here is investment advice. Prices can be delayed or wrong, so check with the exchange before relying on them. Data for this page. How we cover markets.